Is UK evaluation of reproductive tech a model for US?

April 10, 2015 by David Orenstein
Is UK evaluation of reproductive tech a model for US?
Dr. Eli Adashi

When the United Kingdom resoundingly approved mitochondrial replacement therapy in February, it became the first country to give people this new medical option. In parallel it gave the United States serious cause to reflect on how it handles matters of reproductive innovation, argues a trio of experts in the journal Science.

"We have fundamentally different regulatory cultures," said co-author Dr. Eli Adashi, former dean of medicine and biological sciences at Brown University.

The essay's other authors are I. Glenn Cohen of Harvard law and ethicist Julian Savulescu of the University of Oxford.

MRT was conceived to prevent a particular set of health problems from continuing in a family's lineage. The mitochondria are structures within cells that help them produce the energy they need. They have their own genome, separate from the DNA in the cell's nucleus that constitutes the vast majority of the genetic code that makes us who we are. Nevertheless, flaws in mitochondrial DNA can result in certain diseases.

The idea of MRT, therefore, is to get the flawed mitochondria out of the picture when a potential child is just one cell: either an egg or an embryo. In MRT, scientists propose to transplant the nucleus of an egg or zygote into a similar cell from a donor who has healthy mitochondria. The UK is now free to investigate in clinical trials whether resulting babies will thrive, as hoped, with the natural blend of their parents' nuclear DNA, but with the mitochondria of a donor.

Different paths

In the United Kingdom, MRT underwent the evaluation of a specialized, tightly focused institution known as the Human Fertilisation and Embryology Authority. The United Kingdom established HFEA in the wake of its experience grappling with in vitro fertilization, a procedure with scientific and ethical similarities to MRT. HFEA's process, which took about four years, ensured a thorough scientific and ethical review as well as public comment on MRT prior to Parliament's approval on Feb. 3, 2015.

The U.S. experience offers many contrasts, the authors note. Foremost is that there is no specialized body for reviewing these kinds of procedures, although the Food and Drug Administration has asserted jurisdiction over MRT via its Office of Cellular, Tissue, and Gene Therapies of the Center for Biologics Evaluation and Research.

"The FDA is a really broad umbrella that is non-specialized," Adashi said. "In the U.K. it's a highly specialized agency that does nothing else but look into matters of reproduction."

The relevant FDA advisory committee first met in February 2014, and then in September the FDA commissioned an ad hoc committee of the Institute of Medicine to consider the ethical and social policy implications of MRT before its proceeds any further. The IOM is not expected to report for another year.

Other differences include that the United Kingdom simply started considering MRT earlier. Reproductive technologies involving embryos are more legally constrained and ethically controversial in the United States, and although American and British scientists both contributed significantly to the development of MRT, the British in particular regard the breakthrough as a point of national pride, the authors wrote.

It's not just about MRT

Whether or whenever the United States eventually approves MRT, there are also other technologies unique to reproduction and heritability on the policy agenda, the authors noted. These include germline editing, in which scientists could hypothetically edit the nuclear DNA of a sperm, egg, or embryo, and generating eggs or sperm from stem cell-derived somatic cells. In this context of several pending reproductive technology issues, the authors argue that the United States may need to devote the same specialized regulatory resources to the questions as the United Kingdom has.

"This examination of the different approaches taken to the regulation of MRT in the U.K. and the U.S. leads us to reexamine the wisdom of burdening the FDA with the regulatory adjudication of MRT as opposed to adopting a HFEA-like paradigm," the authors wrote. Adashi said MRT in the United States is a test case that can benefit from considering the United Kingdom's successful process.

"How we handle MRT will determine how we handle future breakthrough reproductive technologies," Adashi said.

Explore further: Trio contrast approaches taken by Britain versus the US concerning mitochondrial replacement therapy

More information: Trio contrast approaches taken by Britain versus the US concerning mitochondrial replacement therapy: medicalxpress.com/news/2015-04 … n-mitochondrial.html

Related Stories

Trio contrast approaches taken by Britain versus the US concerning mitochondrial replacement therapy

April 10, 2015
(Medical Xpress)—Glenn Cohen, with Harvard University, Julian Savulescu, with the University of Oxford and Eli Adashi with Brown University have together written and published a Perspectives piece in the journal Science, ...

Science shows ethical questions remain unanswered with 3-person IVF

February 2, 2015
Diseases caused by genetic mutations in the mitochondria – the powerhouses of the cell – can be disabling, or even deadly. That is why mitochondrial replacement therapy (MRT), otherwise also known as three-person IVF ...

A look at the UK's proposal to make babies from 3 people

February 3, 2015
As British lawmakers vote Tuesday on whether to legalize the creation of babies made from the DNA of three people, here are some questions and answers about the proposed techniques and the controversy surrounding them.

UK proposes rules for embryos made from 3 people

December 17, 2014
(AP)—New rules proposed in Britain would make it the first country to allow embryos to be made from the DNA of three people in order to prevent mothers from passing on potentially fatal genetic diseases to their babies.

What can magnetic resonance tractography teach us about human brain anatomy?

September 26, 2011
Magnetic resonance tractography (MRT) is a valuable, noninvasive imaging tool for studying human brain anatomy and, as MRT methods and technologies advance, has the potential to yield new and illuminating information on brain ...

Strong magnetic fields for new insights into the brain

May 13, 2011
Siemens will install three powerful, high-field magnetic resonance tomographs (MRT) at the University of Maastricht, The Netherlands, and thus provide entirely new insights into the human brain. The MRTs are to be dedicated ...

Recommended for you

Women exposed to smoke while in womb more likely to miscarry

July 13, 2017
Women exposed to cigarette smoke while in their mothers' wombs are more likely to experience miscarriage as adults, according to new research from the University of Aberdeen.

Lack of a hormone in pregnant mice linked to preeclampsia

June 30, 2017
(Medical Xpress)—A team of researchers from Singapore, the Netherlands and Turkey has isolated a hormone in pregnant mice that appears to be associated with preeclampsia—a pregnancy-related condition characterized by ...

Aspirin reduces risk of pre-eclampsia in pregnant women

June 28, 2017
Taking a low-dose aspirin before bed can reduce the risk of pre-eclampsia, which can cause premature birth and, in extreme cases, maternal and foetal death.

The biology of uterine fluid: How it informs the fetus of mom's world

June 22, 2017
A developing fetus bathes in a mixture of cellular secretions and proteins unique to its mother's uterus. Before fertilization, the pH of uterine fluid helps create a conducive environment for sperm migration, and afterward, ...

New clues in puzzle over pre-eclampsia and cholesterol regulation

June 21, 2017
Scientists studying a mystery link between the dangerous pregnancy complication pre-eclampsia and an increased risk of heart disease in later life for both mother and child have uncovered important new clues.

Are maternal hormones different when carrying a boy or a girl?

June 15, 2017
With advances in prenatal testing it's now possible to find out whether a pregnancy will result in a male or female baby as early as eight weeks' gestation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.